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DObjectives: Coronary artery disease has been viewed as a relentless, progressive disease. We sought to describe
the prevalence and distribution of regression of native vessel disease in coronary artery bypass patients and char-
acterize its relationship with bypass grafting.
Methods: Among 619 patients who underwent bypass surgery in a radial artery trial, 405 had follow-up angi-
ography available a mean of 6.2  3.1 years (range, 0-14) after surgery. The percentage of diameter stenosis of
each major native coronary vessel was reported by 3 cardiac specialists and classified into grades of nonflow
limiting (0%-39%), moderate (40%-69%), flow limiting (70%-80%), severely stenosed (81%-99%), and
occluded (100%). Native vessel disease regression was defined as decrease in 1 or more grades of stenosis be-
tween the pre- and postoperative angiograms.
Results: A total of 1742 native coronary arteries had preoperative stenosis of at least 40% and were included in
the present analysis, receiving 753 arterial grafts and 391 saphenous vein grafts. Overall, the prevalence of dis-
ease regression was 19.7%, and 45% of patients demonstrated regression in 1 or more vessels. The presence of
an arterial graft increased the likelihood of disease regression (21.3% compared with 16% for venous bypassed
vessels, P ¼ .012) as did the location in the left circulation (22.6% compared with 13.9% for the right circu-
lation, P<.001) and having a flow-limiting (70%) lesion (21.9% compared with 9.8% for moderate lesions,
P<.001).
Conclusions: Native coronary artery disease regression after coronary artery bypass grafting is common and
affected by conduit type, vessel location, and lesion severity. Surgeons must consider these factors when assess-
ing the requirement for bypass grafts in a borderline lesion. (J Thorac Cardiovasc Surg 2014;148:53-9)Atherosclerosis is generally viewed as a chronic, nonremit-
ting disease associated with the formation of lipid-rich, fi-
broatheromatous plaques that compromise the coronary
blood supply, leading to the clinical manifestations of
angina and infarction. The past few decades have seen
the advent of numerous pharmacologic agents aimed at in-
hibiting the formation of such plaques and halting the
progression of existing lesions. More recently, several ran-
domized controlled trials using imaging follow-up have
provided convincing evidence that aggressive lipid-
lowering therapy can retard the progression of coronary ar-
tery lesions1-3 and promote disease regression4-7 in patients
with established coronary artery disease. Accordingly, the
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The Journal of Thoracic and Clowering therapy to achieve very low target levels of choles-
terol in high-risk secondary prevention patients.8
Changes in the anatomy and hemodynamics after coro-
nary artery bypass grafting (CABG) can significantly affect
the evolution of coronary atherosclerosis. Although angio-
graphic disease regression has been evaluated previously,
few of these studies included large numbers of surgical pa-
tients, and, to our knowledge, none have examined the com-
plex relationships among native vessel disease behavior,
conduit type, and patency. We sought to characterize the
prevalence and distribution of native vessel disease regres-
sion in a cohort of patients who had undergone previous
CABG and were angiographically followed up as a part of
a randomized trial. We also assessed the influence of bypass
grafting on native coronary artery disease regression.METHODS
The present study was derived from the Radial Artery Patency and Clin-
ical Outcomes (RAPCO) trial, the design of which has been previously re-
ported.9 The primary aim of the RAPCO trial was to assess the long-term
patency and clinical outcomes of the radial artery, right internal thoracic
artery, and saphenous vein when grafted to the largest non–left anterior de-
scending artery (LAD) target. A total of 619 patients were enrolled in the
RAPCO trial, and all patients underwent primary CABG using cardiopul-
monary bypass.
Angiograms were randomly allocated at intervals of 1, 2, 5, 7, and 10
years, with the bulk weighted toward the second half of the follow-upardiovascular Surgery c Volume 148, Number 1 53
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
CLAS ¼ Cholesterol Lowering Atherosclerosis
Study
HR ¼ hazard ratio
LAD ¼ left anterior descending artery
RAPCO ¼ Radial Artery Patency and Clinical
Outcomes
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Dperiod, because this was anticipated to coincide with most graft failure
events. Additional elective angiograms at 5 and 10 years were offered to
all patients. Patients who had undergone at least 1 postoperative angiogram
were included as a part of the present analysis, and, if more than 1 study
was available, the most recent postoperative angiogram was used.
All angiograms were reported independently by 3 coronary specialists.
Graft failure was defined as occlusion, greater than 80% stenosis or string
sign, and was recorded with any pathologic findings at the proximal or
distal anastomoses. Any disputed findings were further assessed by a fourth
independent observer. The severity of native vessel disease was similarly
assessed by the 3 observers, with the native vessels divided into proximal,
mid, and distal sections, and the location and percentage of diameter steno-
sis recorded. The overall severity of stenosis was taken as the greatest value
from the 3 segments and the mean of the 3 estimations by the cardiac spe-
cialists. In addition to the percentage of stenosis, the lesions were ascribed a
grade, which we used to group the lesions of similar severity or functional
significance. We had noted a pattern whereby observers consistently clas-
sified the same lesions with a particular percentage, depending on whether
the lesion was non–flow-limiting (grade 0), moderate (grade 1), flow-
limiting (grade 2), severe or subtotally occlusive (grade 3), or totally occlu-
sive (grade 4). Grade 0 represented 0% to 39% stenosis; grade 1, 40% to
69%; grade 2, 70% to 80%; grade 3, 81% to 99%; and grade 4, total oc-
clusion. This grading scale allowed for the assessment of disease regression
only, which significantly affects coronary perfusion. The vessels recorded
were the left main stem, LAD and each diagonal branch, left circumflex and
each obtuse marginal branch, right coronary artery, posterior descending
artery, and posterolateral branch. Each of these formed a unique data point.
The severity of disease within each native coronary vessel was
compared on the preoperative and postoperative angiograms and the dura-
tion of imaging follow-up was recorded. A change in the severity of the ste-
nosis was recorded, together with the presence, conduit type, and patency
of any graft to the vessel. A decrease of at least 1 grade was defined as
regression of native vessel disease. If a native vessel lesion changed by
more than 1 grade, the angiograms were reviewed to check that the same
lesion had been compared.
As a part of the trial protocol, the patients received annual telephone and
clinical follow-up from a trained research nurse for at least 10 years after
surgery, and clinical data such as diabetes, hypertension, smoking status,
and symptom control were collated. Lipid studies were obtained by a re-
view of the external pathology databases and general practitioner records,
and all results dating back to the operation date were acquired, if possible.
A graph of lipid measurements against time was compiled for each patient
and the area under the curve calculated. This was then divided by the dura-
tion in years between the date of the first and last readings to obtain the
annualized average lipid exposure. This calculation was repeated for
each of the lipid subfractions, and all values are in mmol/L, unless specified
otherwise. The cholesterol measurements were filtered to include only the
readings taken within 3 months of surgery and within 3 months of the
angiogram date; thus, only the measurements that might have influenced
event occurrence (either graft failure or regression of native vessel disease)
were incorporated into the calculations.54 The Journal of Thoracic and Cardiovascular SurgeAll patients agreed to the surgery, angiograms, annual telephone follow-
up, and surgical reviews. The Austin Hospital Human Research Ethics
Committee approved the RAPCO protocol (project no. H95/086), and addi-
tional approval was gained for the present project as a substudy (project no.
H2006/02690).
Statistical Analysis
Statistical analyses were performed using Statistical Package for Social
Sciences software (SPSS, Chicago, Ill). Dichotomous variables were
analyzed using Pearson’s chi-square test, and continuous variables were
analyzed using the Student t test. The Cox proportional hazards regression
model was used to assess for independent predictors of graft failure and dis-
ease regression. Disease regression was also assessed using the Kaplan-
Meier method, and the log-rank test was used to test for differences
between groups.RESULTS
Of the 619 patients originally enrolled in the RAPCO
trial, 405 patients had follow-up angiograms available at
an average of 6.2  3.1 years (range, 0-13.7) after surgery.
Of the remainder, 176 patients were not due to undergo
angiography because the RAPCO trial was not yet
completed, and a small proportion had died before angiog-
raphy or refused to undergo their assigned angiography,
usually because they were well in the earlier years after sur-
gery. A total of 6077 individual lipid measurements were
obtained. From these angiograms, 3816 native coronary
vessels were examined, and 1742 were found to have preop-
erative stenosis of at least 40% and were included as a part
of the regression analysis. These vessels received 753
mixed arterial grafts and 391 saphenous vein grafts, bypass-
ing a total of 1523 native vessels, because some grafts back-
filled more than 1 coronary artery.Prevalence and Distribution of Native Vessel Disease
Regression
Overall, 182 patients (44.9%) demonstrated regression
in at least 1 native coronary vessel, with an average of
0.85 regressing lesions per patient. The frequency of native
vessel disease regression per patient is listed in Table 1.
The baseline characteristics of the regressing and nonre-
gressing coronary vessels are listed in Table 2. Native cor-
onary lesions were more likely to exhibit regression in
female patients and in those with diabetes. This association
with diabetes was confirmed on multivariate analysis (haz-
ard ratio [HR], 1.56; P ¼ .001; see Table 3).
The prevalence of disease regression by coronary vessel
territory, bypass status, graft type, and graft patency is listed
in Table 4. Of all native coronary vessels that originally
exhibited at least 40% stenosis on their preoperative
angiogram, 19.7% demonstrated regressive disease on the
follow-up angiogram. The overall distribution of disease
regression was 15.7% for the LAD, 24.6% for the left
circumflex, 11.8% for the right coronary artery, 24.4%
for the diagonal branches, 29.2% for the obtuse marginalry c July 2014
TABLE 1. Native vessel disease regression in all patients (n ¼ 405)








Data in parentheses are percentages.
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Dbranches, and 16% for the posterior descending and left
ventricular branch.
The left coronary circulation was more likely to regress
than was the right territory (22.6% vs 13.9%, P< .001
for all coronary vessels), although this was only true for
native vessels bypassed by a graft (22.1% vs 13.4%,
P< .001), and no significant differences were found in
the regression rates between the left and right circulation
in the nonbypassed vessels (25.9% vs 16.7%, P ¼ .110).
Native coronary vessels with flow-limiting lesions preoper-
atively (defined as 70% stenosis) were also more likely to
develop regressive disease compared with their more
moderately stenosed counterparts (40%-69% stenosis;
21.9% vs 9.8%, P < .001). However, again, this only
held true for the bypassed coronary vessels. On multivariate
analysis (Table 3), a location in the left circulation and flow-
limiting preoperative disease were independent predictors
of disease regression in bypassed native vessels after adjust-
ing for conduit type (HR for regression, 1.65 and 2.36;
P ¼ .002 and P<.001, respectively).
Most disease regression occurred in the proximal LAD
(50.8%), followed by the middle segment (21.3%), and
was least likely to occur in the distal section (1.6%). The
left circumflex artery and right coronary artery exhibited
similar patterns of regression, with 41.7%, 26.7%, and
13.3% regression in the proximal, mid, and distal left
circumflex, respectively, and 20.6%, 38.2%, and 17.4%








Follow-up duration (y) 6.13 6.21 .800
Age (y) 63.6 63.2 .613
Male gender (n) 148 (81.3) 206 (92.4) <.001
Diabetes (n) 44 (24.2) 36 (16.1) .043
Preoperative hypertension (n) 100 (54.9) 122 (54.7) .962
Smoking status (n)
Never 58 (31.9) 59 (26.5) .232
Previous 110 (60.4) 145 (65) .342
Current 14 (7.7) 19 (8.5) .762
Surgical status (urgent) (n) 38 (20.9) 51 (22.9) .630
Data in parentheses are percentages.
The Journal of Thoracic and CIn all major coronary vessels, disease regression predomi-
nately occurred proximal to the site of graft anastomosis.
Cholesterol Exposure and Disease Regression
In the overall cohort of native coronary vessels (Table 3),
elevated triglyceride exposure was associated with an
increased likelihood of disease regression (HR, 1.21;
P ¼ .032), although high-density lipoprotein cholesterol
and low-density lipoprotein cholesterol failed to show any
significant correlations. Elevated triglycerides showed a
trend toward increased disease regression in revascularized
native vessels, although this failed to reach significance
(HR, 1.18; P ¼ .090).
Influence of CABG on Disease Regression
No differences were found in the rates of regression
between the bypassed and nonbypassed coronary vessels.
However, the presence of an arterial graft conferred an
advantage, with 21.3% of arterially bypassed vessels
exhibiting regression compared with 16% of venous
bypassed vessels (P ¼ .012). Kaplan-Meier analysis
confirmed this finding, with arterially grafted vessels signi-
ficantly more likely to undergo disease regression (regres-
sion rate, 33.8% for arterially bypassed and 25.6% for
vein bypassed at 10 years, P¼ .036). The rates of regression
were similar between vessels that had received an internal
thoracic artery graft and those revascularized with a radial
artery. The presence of an arterial graft remained predictive
of disease regression, irrespective of vessel location (left or
right) and severity of preoperative stenosis on multivariate
analysis (HR, 1.35; P ¼ .041; Table 3). Graft patency per
se had no effect on disease regression.
The incidence of disease regression in the nonbypassed
native coronary vessels was unaffected by vessel location,
the severity of preoperative disease, and cholesterol
exposure, although the numbers in this group might have
been too small to detect any associations (n ¼ 219).
Influence of Disease Regression on Graft Patency
Of 753 arterial conduits and 391 saphenous vein grafts,
62 (3.5%) and 85 (4.8%) were occluded on the follow-up
angiogram. An arterial graft was at significantly lower
risk of failure than a vein graft (HR for failure, 0.393;
P<.001; Table 5). Disease regression in the native coronary
vessel increased the hazards of arterial graft failure
(HR, 1.91; P ¼ .022) but not vein graft failure.
DISCUSSION
A number of trials in the previous decade have shown that
active lipid-modulating therapy, primarily centered onHMG-
coenzyme A reductase inhibitors (statins), can halt the pro-
gression of coronary atherosclerosis1-3 and reverse disease
in patients with coronary artery disease.4-7 However, few of
these studies have characterized regression of coronaryardiovascular Surgery c Volume 148, Number 1 55
TABLE 3. Cox proportional hazards model for predictors of disease regression in native vessels
Variable
All vessels (n ¼ 1742) Bypassed vessels (n ¼ 1523) Nonbypassed vessels (n ¼ 219)
HR P value HR P value HR P value
Age 1.021 .002 1.023 .003 1.020 .287
Male gender 0.791 .147 0.768 .125 0.800 .675
Diabetes 1.564 .001 1.677 <.001 1.062 .872
Preoperative hypertension 0.992 .944 1.004 .972 0.983 .957
Smoking (current) 0.904 .659 0.960 .867 1.116 .859
Surgery status (urgent) 1.141 .340 1.215 .186 0.797 .596
Left circulation 1.804 <.001 1.648 .002 1.590 .173
Flow-limiting preoperative lesion (70%) 2.367 <.001 2.357 <.001 1.827 .160
HDL cholesterol 1.103 .659 1.143 .574 0.864 .804
LDL cholesterol 1.160 .125 1.169 .133 0.965 .903
Triglycerides 1.207 .032 1.175 .090 1.372 .188
Bypassed 0.731 .054 — — — —
Arterial graft — — 1.350 .041 — —
Graft failure — — 1.033 .859 — —
HR, Hazard ratio; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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D atherosclerosis in those who have undergone previous
CABG. The aim of the present study was to describe the
distribution of native vessel disease regression in surgical
patients and its relationship with CABG.
Prevalence of Native Vessel Disease Regression
Overall, about one fifth of native coronary vessels
exhibited regressive disease after long-term follow-up
(mean, 6.2 years), and almost one half of all patients
demonstrated lesion regression in at least 1 native coronary
artery. The Cholesterol Lowering Atherosclerosis Study
(CLAS)-I,10,11 which randomized 162 patients with
previous CABG to either combined colestipol-niacin or
placebo therapy, reported angiographic disease regression
at 2 years in 16.2% of drug-treated subjects and 2.4% of
placebo-treated patients. CLAS-II12 performed a third
angiogram in 103 patients at 4 years after the original
randomization and found disease regression in 18% of
patients within the treatment group and 7% within the
placebo group. The rate of regression in our series (45% of
all patients with  1 vessels exhibiting regression) more
closely resembles that of the lipid treatment group in the
CLAS-II than that of the placebo group. Even in coronary
vessels hemodynamically unaffected by a bypass graft, the
incidence of disease regression remained at approximately
20%. Whether this was related to more intense secondary
management of cardiovascular risk factors, changes in
surgical technique and conduit selection in the 20 years since
the CLAS report was published or a combination of these
factors remains to be clarified.
Distribution of Native Vessel Disease Regression
Our data have shown that revascularized coronary vessels
in the left circulation and those with pre-existing severe
stenosis of more than 70% were most likely to undergo56 The Journal of Thoracic and Cardiovascular Surgedisease regression. Differences in flow characteristics
between the left and right circulation and variations in the
degree of shear stress on the vessel wall might offer more
favorable conditions for disease reversal on the left.13,14
In a recent angiographic study of disease progression in
4960 subjects 5.5 years after primary CABG, Dimitrova
and colleagues15 reported greater rates of progression in
the inferior territory (46%) than in that of the anterior
territory (18%). The present results suggest that the flow
dynamics promoting an atherogenic environment in the
right circulation and increasing disease progression might
also conversely affect disease regression in the left.
Atherosclerotic lesion morphometry could also differ
between the left and right circulation and between severely
and moderately stenosing lesions. Pathologic studies of
human coronary arteries have shown a tendency for
ruptured plaques and thin-capped fibroatheromas (those
most vulnerable to rupture and thrombosis) to cluster within
the proximal LAD and left circumflex arteries.16 It has been
suggested that vulnerable plaque might be the form of
atherosclerosis most susceptible to disease regression,17 in
keeping with our findings of disease regression being the
most prevalent in the left coronary circulation.
Additionally, smaller coronary arteries will likely exhibit
greater degrees of regression for a given volume of plaque
(just as in small vessels, a small volume of plaque is more
likely to create flow-limiting stenosis). This relationship
between coronary size and the detection of regression most
likely underlies the preponderance of regression in the
circumflex artery and smaller coronary branches (rather
than the larger LAD and right coronary artery) and the greater
prevalence inwomenoverall. Thefindingof increaseddisease
regression indiabetic patientswas unexpected, although these
patients might have been exposed to more intense secondary
preventative measures, favoring more disease regression.ry c July 2014
TABLE 4. Prevalence and distribution of disease regression stratified






All vessels (n ¼ 1742) 344 (19.7) <.001*
Left circulation (n ¼ 1179) 266 (22.6)
Right circulation (n ¼ 563) 78 (13.9)
LAD (n ¼ 389) 61 (15.7)
LAD branches (D1 þ D2; n ¼ 180) 44 (24.4)
LCx (n ¼ 244) 60 (24.6)
LCx branches (OM1 þ OM2; n ¼ 318) 93 (29.2)
RCA (n ¼ 288) 34 (11.8)
RCA branches (PDA þ LVBr; n ¼ 275) 44 (16.0)
All vessels (severity of preoperative stenosis) <.001y
Moderate (40%-69%; n ¼ 305) 30 (9.8)
Flow limiting (70%; n ¼ 1437) 314 (21.9)
Bypass status .296z
Bypassed (n ¼ 1523) 295 (19.4)
Nonbypassed (n ¼ 219) 49 (22.4)
Bypassed vessels (n ¼ 1523) <.001x
Left circulation (n ¼ 1044) 231 (22.1)
Right circulation (n ¼ 479) 64 (13.4)
LAD (n ¼ 384) 60 (15.6)
LAD branches (D1 þ D2; n ¼ 123) 28 (22.8)
LCx (n ¼ 212) 50 (23.6)
LCx branches (OM1 þ OM2; n ¼ 285) 87 (30.5)
RCA (n ¼ 225) 27 (12.0)
RCA branches (PDA þ LVBr; n ¼ 254) 37 (14.6)
Graft type .012jj
Arterial (n ¼ 956) 204 (21.3)
Venous (n ¼ 567) 91 (16.0)
LITA (n ¼ 431) 78 (18.1)
RITA (n ¼ 197) 49 (24.9)
RA (n ¼ 327) 77 (23.5) .731{
SVG (n ¼ 567) 91 (16.0) .006#
Graft patency .181**
Patent (n ¼ 1324) 249 (18.8)
Failed (n ¼ 197) 45 (22.8)
Bypassed vessels (severity of preoperative
stenosis)
<.001yy
Moderate (40%-69%; n ¼ 249) 22 (8.8)
Flow limiting (70%; n ¼ 1274) 273 (21.4)
Nonbypassed vessels (n ¼ 226) .110zz
Left circulation (n ¼ 135) 35 (25.9)
Right circulation (n ¼ 84) 14 (16.7)
LAD (n ¼ 5) 1 (20)
LAD branches (D1 þ D2; n ¼ 57) 16 (28.1)
LCx (n ¼ 32) 10 (31.3)
LCx branches (OM1 þ OM2; n ¼ 33) 6 (18.2)
RCA (n ¼ 63) 7 (11.1)








Nonbypassed vessels (severity of preoperative
stenosis)
.092yy
Moderate (40%-69%; n ¼ 56) 8 (14.3)
Flow limiting (70%; n ¼ 163) 41 (25.2)
Data in parentheses are percentages. LAD, Left anterior descending; LCx, left circum-
flex; RCA, right coronary artery; PDA, posterior descending artery; LVBr, posterolateral
branch; LITA, left internal thoracic artery;RITA, right internal thoracic artery;RA, radial
artery; SVG, saphenous vein graft;OM, obtuse marginal. *Left versus right. yModerate
versus severe stenosis. zBypassed versus not bypassed. xLeft versus right circulation.
jjArterial versus venous grafts. {RITA versus RA. #RA versus SVG. **Failed versus
patent grafts. yyModerate versus severe lesions. zzLeft versus right circulation.
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Unlike previous statin trials that supported a strong
association between intensive lipid control and regression
of coronary atherosclerosis,4-6 elevated triglycerides wasThe Journal of Thoracic and Cthe only lipid subfraction in our analysis that increased
the rates of disease regression, with low-density lipoprotein
and high-density lipoprotein cholesterol showing no effect.
There could be a number of reasons (and possibly
limitations of the present study) that could account for
this relatively weak and counterintuitive association.
Accurate data on the type, duration, and dosing of any
lipid-lowering therapies were not available during the
10-year period of follow-up and could not be correlated
with the lipid readings. Thus, it is possible that these agents
exerted an influence on regression by way of pleiotropic
effects, independent of their lipid-lowering capabilities.Influence of CABG on Native Vessel Disease
Regression
The presence of a bypass graft (either venous or arterial)
per se did not affect regression of native vessel disease. This
would imply either no effect on regression of coronary
disease or opposing effects between the arterial and venous
bypass conduits. The latter hypothesis was supported by our
finding that an arterially bypassed coronary vessel was more
likely to have a regressing lesion than was a venous
bypassed vessel. This advantage of arterial grafts in
promoting regression in the corresponding native coronary
vessel was found to be independent of the coronary territory
(either left or right), graft patency, and severity of the
preoperative lesion on multivariate analysis. Dimitrova
and colleagues15 recently reported a possibly related
phenomenon in which the arterial grafts appeared to protect
the native circulation against disease progression. Arterial
grafts are metabolically active vessels, with their
endothelium able to release vasoactive substances and
endothelial progenitor cells, which might protect the native
circulation from disease progression and might also induce
regression as an extension of this effect. Arterial grafts
could, therefore, interact with the native circulation in a
dynamic fashion, such that regression of atherosclerosis in
the native vessel is matched by occlusion of the correspond-
ing graft, which is then no longer required to maintain
perfusion, allowing for overall functional revascularization.ardiovascular Surgery c Volume 148, Number 1 57
TABLE 5. Cox proportional hazards model for predictors of graft patency
Variable
All grafts (n ¼ 1144) Arterial grafts (n ¼ 753) Vein grafts (n ¼ 391)
HR P value HR P value HR P value
Age 1.007 .492 0.999 .954 1.018 .195
Male gender 0.693 .120 0.813 .583 0.565 .064
Diabetes 0.982 .932 0.886 .723 1.033 .907
Preoperative hypertension 1.136 .466 1.516 .128 0.992 .971
Smoking (current) 1.103 .742 0.320 .121 1.928 .068
Surgery status (urgent) 0.983 .932 1.092 .770 0.853 .569
Native vessel disease regression 1.343 .151 1.910 .022 0.850 .601
Arterial graft 0.393 <.001 — — — —
HR, Hazard ratio.
Acquired Cardiovascular Disease Zhu et al
A
C
DThis benefit of arterial grafts, in addition to their excellent
long-term patency, might contribute to the better clinical
outcomes seen in patients with multiple arterial grafts.
Patients after coronary stent placement have also been
reported to demonstrate disease regression. Kimura and
colleagues18 described an early phase of restenosis until
6 months after percutaneous coronary intervention, a
regression phase from 6 months to 3 years, and a late repeat
narrowing phase after 4 years. The patients in the present
study exhibited disease regression an average of 6.2 and
up to 14 years postoperatively, and the absence of any late
repeat narrowing phase after 4 years might help facilitate
the superior long-term revascularization and excellent
clinical outcomes after bypass surgery. The mechanisms
underlying the different disease behavior between stenting
and grafting remain unclear.Influence of Disease Regression on Graft Patency
Thus far, we have characterized the lesion behavior in
native coronary vessels after coronary surgery. Additional
analysis showed that disease regression in the native vessel
will, in turn, affect arterial graft patency, increasing the risk
of graft failure by almost twofold (P¼ .022). This can occur
if the regressing native vessel lesions increase coronary flow
competition to the graft and predispose the arterial graft to
occlusion.19 The use of an arterial graft could therefore be
seen as acting in harmony with the native circulation,
enabling regression of plaques matched by corresponding
failure of a graft when it is no longer required to maintain
perfusion.Study Limitations
Several limitations apply within the present study. Our
analysis was performed as a part of a clinical trial using
angiographic evaluation, and the details of lesion topo-
graphy and morphometry were not available. Angiographic
detection of regression could also have underestimated the
true prevalence of regression, recognizing that subtle
degrees of regression are likely much more common than
angiographically visible regression. The change in the58 The Journal of Thoracic and Cardiovascular Surgepercentage of diameter stenosis, used in the present study
as a surrogate for the severity of stenosis, might not
correlate well with the atheroma burden nor does it adjust
for the effects of outward coronary artery remodeling.
Additional assessment using intravascular ultrasonogra-
phy would provide more in-depth analysis of the complex
relationships among these factors, and quantitative comput-
erized angiography might more accurately detect lesion
regression than the estimation of stenosis by 3 observers.CONCLUSIONS
Regression of native vessel disease can be observed in
almost one half of all patients during long-term follow-up
and is favored by arterial coronary bypass conduits, location
in the left coronary circulation, and the presence of a
severely stenosing preoperative lesion. Surgeons will
recognize how common is such regression when assessing
the requirement of a bypass graft in a borderline lesion.References
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